Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 9INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Tumor-Agnostic 6Thoracic 5Other solid neoplasm 3Gynecologic 2Genitourinary 2CNS 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Neoplasms 2Glioblastoma 2Brain Neoplasms 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × cediranib × CNS × Clear all
NCT00777153 2016-12-28

REGAL

AstraZeneca

Phase 3 Completed
423 enrolled 13 charts
CNS

Glioblastoma, Neoplasms

NCT00503204 2009-11-25

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

AstraZeneca

Phase 1 Completed
20 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡